Expression and clinical significance of CXCR5/CXCL13 in human non-small cell lung carcinoma

RAJESH SINGH1, PRANAV GUPTA1, GOETZ H. KLOECKER2, SHAILESH SINGH1 and JAMES W. LILLARD Jr1

1Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310-1495; 2James Graham Brown Cancer Center, University of Louisville, KY 40202, USA

Received July 2, 2014; Accepted August 11, 2014

DOI: 10.3892/ijo.2014.2688

Abstract. CXCR5 and/or CXCL13 expression is elevated in certain carcinomas and lymphomas. To determine if these factors are involved in progression of non-small cell lung cancer (LuCa), we evaluated their expression in patients with various forms of this disease. Lung biopsies from patients with non-neoplastic cells (n=8), squamous cell carcinoma (Scc; n=24), or adenocarcinoma (Ac; n=54) were stained for CXCR5. Histopathological analysis of these samples showed significantly higher expression of CXCR5 (p<0.001) in carcinomas (i.e., SCCs and ACs) relative to non-neoplastic lung tissue. Nuclear and membrane CXCR5 intensities were highest in ACs, with median values of 185 and 130, respectively, followed by SCCs with median values of 170 and 110, respectively. The lowest nuclear and membrane expressions of CXCR5 were found in non-neoplastic tissues, having median values of 142 and 90, respectively. Sera from SCC patients (n=17), AC patients (n=14), and healthy controls (n=9) were tested for the presence of CXCL13. Serum CXCL13 levels in LuCa patients were higher than in healthy controls. CXCR5 expression in cell lines of human non-small cell lung carcinoma (NCI-H1915) and small cell lung carcinoma (SW-1271) were evaluated by flow cytometry. CXCR5 expression was higher in NCI-H1915 cells relative to SW-1271 cells. The functional significance of CXCR5 expression was tested in a migration assay. In response to CXCL13, more NCI-H1915 cells migrated than SW-1271 cells. These findings suggest that the CXCR5-CXCL13 axis influences LuCa progression. After validation in larger patient groups, CXCR5 and CXCL13 may prove useful as biomarkers for LuCa. Correspondingly, blockade of this axis could serve as an effective therapy for LuCa.

Introduction

Lung cancer (LuCa) is the leading cause of cancer-related deaths among men and women worldwide and is responsible for more deaths than breast, colon, and prostate cancer (PCa) combined (1). LuCas are broadly classified into small cell lung carcinomas (SCLCs) and non-small cell lung carcinomas (NSCLCs). About 85% of all LuCas are identified as NSCLCs; 75% of these are metastatic or advanced at diagnosis (2). Although patients presenting with stage I-II diseases are usually treated with surgery, half of these cases subsequently develop metastatic disease that proves to be fatal. Despite many efforts, little has been achieved for the treatment of this deadly disease. Advances in understanding the factors involved in LuCa progression and development of prognostic and predictive markers have the potential to improve therapeutic outcomes.

NSCLC growth and metastases to secondary sites are highly regulated events, which involve cellular transformation, establishment of a pro-angiogenic environment, and migration and invasion of tumor cells. This latter process is analogous to leukocyte trafficking. To this end, chemokines and their receptors play a major role. Chemokines are small, 8-10 kDa proteins involved in directional migration of cells towards a chemokine gradient that is detected by g-protein-coupled chemokine receptors. These chemotactic cytokines are further classified into CC, CXC, C and CX3C family members, based on their cysteine residues and disulfide bonds. These chemokines are essential for homeostasis and function of the immune and stem cell systems. In recent years, a new role of chemokines has emerged, which involves neoplastic transformation of cells, tumor cell growth and survival, and organ-specific metastasis during carcinogenesis (3,4). Of the CXC chemokines, CXCR4 is involved in NSCLC progression. NSCLC tumors and cell lines express CXCR4, and, in mouse models, anti-CXCR4 antibody reduces tumor metastases. Further, organs to which NSCLCs preferentially metastasize constitutively express CXCL12, a natural ligand for CXCR4 (5). To our knowledge, this is the first study to demonstrate the association of CXCR5 and CXCL13 with NSCLC. In contrast to CXCR4, which is expressed by normal and malignant hematopoietic and non-hematopoietic cells (6), CXCR5 is expressed primarily by mature, recirculating B cells and by small subsets of CD4+ 

Correspondence to: Professor James W. Lillard Jr, Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310-1495, USA
E-mail: jlillard@msm.edu

Key words: chemokine, chemokine receptors, CXCR5, lung cancer, non-small cell lung carcinoma
and CD8+ T cells. The migration of these leukocytes into and within lymph nodes is controlled by CXCR5-CXCL13 interactions (6,7). Recently, it has been recognized that the CXCR5-CXCL13 axis is associated with various hematologic (7-10) and solid tumor malignancies (11-16). Indeed, CXCR5 and CXCL13 are expressed in prostate, breast, neuronal, and oral carcinomas (11,13-15). Previously, we elucidated the molecular mechanisms and functional significance of CXCR5 and CXCL13, whereby this axis promotes PCA cell migration, invasion, and differential matrix metalloproteinase (MMP) expression (17). We also showed that CXCL13-mediated invasion of PCA cells requires Akt and ERK1/2 activation, suggesting a new role for DOCK2, a protein involved in intracellular signaling, in proliferation of hormone-refractory CXCR5-positive PCA cells (18).

Based on these findings, we investigated the expression of CXCR5 and CXCL13 in patient samples of NSCLCs, evaluating the expression of CXCR5 in normal, squamous cell carcinoma (SCC), and adenocarcinoma (AC) tissues by immunohistochemical staining. To determine the association of CXCL13 with NSCLC progression, serum CXCL13 levels were analyzed for both subtypes of NSCLCs. Furthermore, the expression patterns of CXCR5 in human LuCa cell lines were determined, and the findings were correlated with clinicopathological features to evaluate the role of CXCR5 in NSCLC progression. To understand the biological significance of CXCR5 over-expression in NSCLCs, the migration potential of LuCa cells via CXCL13 was analyzed. These results demonstrate the association with and point to a role of CXCR5 and CXCL13 in NSCLCs.

Materials and methods

Tissue specimens. Tissue microarray (TMA) slides containing malignant (n=78), non-neoplastic (n=8), and other (n=12) lung tissues (n=98) were purchased from AccuMax Array (ISU Abxis Co., Ltd., Seoul, Korea). These spots were generated from lung biopsies of 45 cases diagnosed with NSCLCs with histological subtypes of AC (n=27), SCC (n=12), and others (n=6); and eight non-neoplastic cases. To construct TMAs, two cores (1 mm in diameter) per patient were arrayed on a receiver paraffin block, and, concerning the histopathology, a qualified pathologist validated each core of the TMAs twice for class and grade of the tumor. LuCa TMAs consisted of tumors from 45 patients and represented all histopathological subtypes reported for LuCa. The total of 98 spots represented eight non-neoplastic, 54 ACs, 24 SCCs, and 12 others.

Immunohistochemistry. TMA slides containing biopsies obtained from malignant and non-neoplastic cases were stained for CXCR5. Briefly, TMAs were de-paraffinized in xylene and rehydrated through a graded series of ethanol (100, 95 and 70%) for 5 min in each series and washed in distilled water. After de-paraffinization, antigen retrieval was accomplished by incubating TMAs with 0.01 M EDTA (pH 8.0) in a pressure cooker for 5 min. Slides were then cooled in running water and transferred to Tris-buffer (pH 7.6). The endogenous peroxidase activity was blocked by incubating the slides with 3% H2O2 in phosphate-buffered saline (PBS) for 5 min. The slides were then rinsed three times with de-ionized water followed by Tris-buffer (pH 7.6). Following washing, Fc blocking was accomplished by incubating the slides with Fc Block (Innovex Biosciences, Inc., Richmond, CA, USA) for 30 min at room temperature (RT) in a humidity chamber. To reduce non-specific binding, the sections were washed with Tris-buffer and incubated with 3% normal goat serum for 1 h at RT. The slides were then washed with Tris-buffer, and sections were incubated with 5 μg/ml of mouse anti-CXCR5 antibody (R&D Systems, Minneapolis, MN, USA) for 90 min at RT in a humidity chamber. Negative control slides were incubated with 5 μg/ml of mouse isotype control antibody (R&D Systems). Following incubation, sections were washed with Tris-buffer and developed with a 3,3′-diaminobenzidine (DAB) (Vector Laboratories, Inc., Burlingame, CA, USA) as a chromogen for 25 min at RT. The sections were also incubated with alkaline phosphatase (AP)-conjugated goat anti-mouse antibody (Invitrogen Life Technologies, Grand Island, NY, USA) for 20 min at RT and developed with AP-New Magenta (BioFX Laboratories, Inc., Owings Mills, MD, USA) substrate for 25 min at RT. Counterstaining was with hematoxylin (Sigma, St. Louis, MO, USA). Subsequently, sections were washed with water, dehydrated in 70, 95%, and absolute alcohol for 5 min each, passed through xylene three times for 1 min each, and mounted with Permount (Sigma). The immunopositivity of the sections was analyzed using an Aperio ScanScope scanning system (Aperio Technologies, Vista, CA, USA).

Quantitation of immunohistochemical staining. To analyze the immunohistochemical staining, virtual slides were created from the stained samples after scanning each specimen with an Aperio ScanScope scanning system (Aperio Technologies). The ScanScope generated true-color digital images of each stained sample, which were viewed using Aperio ImageScope v.6.25 software. The algorithm for determining the intensity of membrane-specific staining was used to calculate, for each sample, the staining intensity and percent of target labeled by digitally analyzing the color intensity. A color markup image for each slide was obtained based on membrane staining intensity. The output was viewed as determinations of staining intensity ranging from 0-3 to correlate with conventional manual scoring methods (where 0, negative and 3, strong staining), and statistical analyses were performed using the means of these values.

Quantitative enzyme-linked immunosorbent assay (ELISA) for serum CXCL13. Sera from patients with SCCs (n=17), ACs (n=14), and healthy controls (n=9) were obtained from the James Graham Brown Cancer Center, University of Louisville, KY, USA. Healthy donors had no active lung disease or symptoms at the time of blood collection. All subjects gave written informed consent and were approved by the University of Alabama at Birmingham Institutional Review Board (IRB). Subsequently, the University of Louisville IRB approved the use of these diagnostic specimens in accordance with the Department of Health and Human Service Policy for the Protection of Human Research Subjects 45 CFR 46.101(b) 2 and use of archived de-identified materials. Serum CXCL13 levels were measured by human CXCL13 Quantikine ELISA (R&D Systems), following the manufacturer’s instructions. Briefly, 100 μl of assay diluent (provided with the kit), followed by
50 µl of standard, control, or samples (sera from patients and healthy controls) were added in different wells of a 96-well plate and incubated for 2 h at RT. Following washing four times with Quantikine Wash Buffer 1 (provided with the kit), 200 µl of conjugate (antibody) was added to each well, and the plate was incubated for 2 h at RT. The plate was washed further, and 200 µl of substrate solution (provided with the kit) was added to each well. The plate was incubated for 30 min in the dark at RT. Following incubation, 50 µl of stop solution was added to each well, and the plate was read in an ELISA reader at 450 nm. The ELISA assays were capable of detecting >1 pg/ml of CXCL13.

Cell cultures. Human NSCLC NCI-H1915 (CRL-5904) and small cell lung carcinoma SW-1271 (CRL-2177) cell lines were obtained from American Type Cell Culture (ATCC) (Teddington, UK). NCI-H1915 cells were cultured in RPMI-1640 media (Mediatech Cellgro, Herndon, VA, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Sigma), 100 µg/ml streptomycin, and 100 U/ml penicillin (Sigma) at 37°C with 5% CO2. SW-1271 cells were cultured in Leibovitz's L-15 Medium (Mediatech Cellgro) supplemented with 10% FBS, 100 µg/ml streptomycin, and 100 U/ml penicillin at 37°C with 100% air. Cells were split twice a week to ensure optimal growth conditions.

Functional analysis of CXCR5 expression. For both LuCa cell lines, CXCR5 surface expression was analyzed by flow cytometry. Briefly, LuCa cells were washed three times in PBS [supplemented with 1% bovine serum albumin (BSA)], and treated with 1 µg of FC Block (BD Biosciences, San Jose, CA, USA) per 10^5 cells for 15 min at RT. FC-blocked cells were incubated with 1 µg of fluorescein-conjugated mouse anti-human CXCR5 or fluorescein-conjugated mouse IgG2a isotype control antibodies (R&D Systems) per 10^5 cells for 1 h at 4°C. Following staining, the unbound antibodies were removed by washing the cells three times with fluorescence-activated cell-sorting (FACS) buffer (1% BSA in PBS). The labeled cells were then fixed in 500 µl of 2% paraformaldehyde solution and analyzed by flow cytometry using a FACSScan flow cytometer (BD Biosciences). The flow cytometry data were analyzed with FlowJo software. The stained cells were also analyzed by an Amnis ImageStream system (Amnis Corp., Seattle, WA, USA).

Migration assay. Cell migration was assessed with a BD BioCoat™ migration chamber system (BD Biosciences). Briefly, Matrigel inserts were hydrated for 2 h with 500 µl of serum-free Dulbecco's modified Eagle's medium at 37°C with 5% CO2, CXCL13 (PeproTech, Rocky Hill, NJ, USA), at a concentration of 0 or 100 ng/ml, was added to the bottom chamber containing serum-free RPMI medium. Next, NCI-H1915 and SW-1271 cells were incubated with isotype control or anti-human CXCR5 antibody at a concentration of 1 µg/ml (both from R&D Systems) for 1 h at 37°C with 5% CO2 and added to the top chambers in serum-free RPMI medium at 10,000 cells per well. The cells were allowed to migrate for 8 h at 37°C under 5% CO2. Non-migrating cells on the upper surface of the membrane were removed with a cotton swab. The cells that migrated to the lower surface were fixed with 100% methanol for 5 min at RT, stained with crystal violet for 2 min, and rinsed twice with distilled water. The membranes were placed on glass slides. The migrated cells were counted by microscopy at x40 magnification. The experiments were performed in triplicate and repeated three times.

Statistics. The intensity of CXCR5 and CXCL13 expression by lung TMAs was tested for normality assumptions using the Shapiro-Wilk test and was transformed to a Log scale. The general linear models procedure was used to test the association of CXCR5 and CXCL13 expression and disease condition using SaS v.9.1.3 statistical analysis software. Results were declared significant at α level of 0.001. The experimental data were compared using a two-tailed Student's t-test and expressed as mean ± SEM. The results were analyzed using the Stat View II program (Abacus Concepts, Inc., Piscataway, NJ, USA) and were labeled statistically significant if p-values were <0.01. With Cell Quest Software, the Kolmogorov-Smirnov (K-S) two-sample test was used to calculate the statistical significance of the CXCR5 histograms.
Results

**Immunohistochemical analyses demonstrate CXCR5 is overexpressed in LuCa tissues relative to non-neoplastic tissues.** LuCa TMAs, consisting of 98 biopsy areas, generated from biopsies of malignant (SCC and AC) and non-neoplastic cases, were analyzed for CXCR5 expression by immunohistochemistry. CXCR5 was expressed in tissues collected from SCC and AC cases (p<0.001) relative to non-neoplastic tissues, in which no signal was detected (Fig. 1). Average positive, nuclear, and membrane CXCR5 intensities were quantified in non-neoplastic, SCC, and AC cases using image analysis Aperio ImageScope v.6.25 software (Figs. 2-4). These intensities were highest in ACs, with median values...
of 128, 185, and 130, respectively; followed by SCC with median values of 118, 170, and 110, respectively; and lowest in non-neoplastic tissues with median values of 92, 142, and 90, respectively. Further, CXCR5 expression correlated with stage (T) and nodal involvement (N) of tumors in both SCC and AC tissues. In SCCs, total average CXCR5 expression in cases with T1 (median value, 116) was essentially equal to cases with ≥T2 (median value, 115) but lower than ≥T2 in ACs (median value, 120). However, the average positive pixel count of CXCR5 expression in ACs was higher in T1 (average value, 154) than in ≥T2 (average value, 138) there was higher CXCR5 expression for cases with ≥N1 (median value, 121) than...
N0 (median value, 116) in SCCs, but there was little difference for AC cases (median value 124) (Fig. 2). Both nuclear and membrane CXCR5 expression was higher in T1 than in ≥T2 SCCs (median values, 174 and 110 vs. 162 and 108, respectively). Although nuclear and membrane CXCR5 expressions in T1 (median values, 186 and 132, respectively) were slightly higher than ≥T2 (median values 185 and 128, respectively) of ACs, similar to SCCs, the maximum expressions of both nuclear and membrane CXCR5 intensities in ≥T2 ACs (average values 198 and 162, respectively) were higher relative to the maximum
for T1 ACs (average values, 194 and 150, respectively). Further, both nuclear and membrane CXCR5 intensities were higher in SCCs with ≥N1 (median values, 172 and 112) relative to SCCs with N0 (median values, 162 and 108). However, in AC tissues, both nuclear and membrane CXCR5 intensities were essentially equal in N0 and ≥N1, with median values of 186 and 122, respectively (Figs. 3 and 4).

Levels of serum CXCL13 are elevated in LuCa patients. Serum CXCL13 in SCC and AC patients was quantified with a commercially available ELISA kit. Similar to histopathological findings of CXCR5, the serum CXCL13 level was significantly higher for AC followed by SCC patients, relative to healthy controls. The median values of CXCL13 expression (pg/ml) in serum of ACs and SCCs were 42 and 32, respectively (Fig. 5). However, the CXCL13 expression in healthy controls was lower, with a median value of 15.

CXCR5 is over-expressed on LuCa cell lines. CXCR5 expression was evaluated in human NSCLC (NCI-H1915) and SCLC (SW-1271) cell lines using flow cytometry and images were captured by a flow-based imaging system (Amnis ImageStream system). Both cell lines stained positive for CXCR5 and a nuclear stain, DRAQ5. The intensity of membrane CXCR5 expression, measured in terms of mean fluorescence intensity (MFI), was higher in NSCLC (NCI-H1915) cells, relative to SCLC (SW-1271) cells (MFI, 115.6 vs. 86.4) (Fig. 6A). CXCR5 was expressed on membranes of both cell lines, as seen by their composite images (Fig. 6B).

LuCa cells migrate following the CXCR5-CXCL13 interaction. The functional significance of CXCR5 expression by LuCa cell lines was demonstrated by the capacity of NCI-H1915 and SW-1271 cells to migrate towards CXCL13. Both types of cells migrated to media with CXCL13, relative to media without CXCL13 (Fig. 7). However, the numbers of NCI-H1915 cells that migrated in response to CXCL13 was higher than the numbers of SW-1271 cells. CXCR5-CXCL13 dependent chemotaxis was abrogated by anti-CXCR5 antibodies. Cells treated with isotype control antibodies served as controls, in which no inhibition in the number of migratory cells was observed in response to CXCL13.

Discussion

Chemokines/chemokine receptors apparently facilitate tumor dissemination, leading to metastasis, growth, and cell survival (19-21). Few studies have addressed the significance of chemokine/chemokine receptor expression in NSCLCs. Higher expressions of CXCR1, CXCR2, and CXCR4 with their ligands CXCL5, CXCL8, and CXCL12 appear to be associated with tumor angiogenesis, metastasis, and poor survival in NSCLCs (5,22-26). Until now, there were no comprehensive studies regarding the presence or potential role of CXCR5 in NSCLCs.

CXCR5 is a principal regulator for targeting T cells, B cells, and dendritic cells into secondary lymphoid organs. The CXCR5-CXCL13 axis is involved in development and progression of solid tumors, e.g., breast cancers and neuronal cancers (13,14). Recently, we demonstrated a differential expression of CXCR5 in PCa cell lines correlated with PCa progression (17,18). These findings provided the rationale for the present study, which characterizes CXCL5 and CXCR13 expression and interactions during LuCa progression.

The expression of CXCR5 and/or CXCL13 was assessed in LuCa tissues, serum, and LuCa cell lines. Higher CXCR5 expression in LuCa tissues, relative to non-neoplastic tissues and elevated serum CXCL13 in LuCa patients relative to healthy controls correlated with disease progression. SCCs and ACs are two major histologic types of NSCLCs. Patients with ACs have a poorer prognosis than those with SCCs (27,28). However, the differences in biological aggressiveness between SCCs and ACs of the lung are not well understood. We found higher nuclear and membrane intensities of CXCR5 in ACs relative to SCCs. Our findings demonstrate that CXCR5 is differentially expressed in lung carcinomas depending on stage of the disease. Moreover, differential nuclear and membrane CXCR5 expression in SCCs and ACs correlate with their aggressiveness. We further investigated CXCR5 expression in relation to tumor stage (T) and nodal metastasis (N). Although we did not find a statistically significant correlation between CXCR5 expression and tumor stage or nodal metastasis, there was increased CXCR5 expression in SCC cases with nodal metastases. Hence, it is plausible that the CXCR5-CXCL13 axis is involved in tumor dissemination to lymph nodes. We did not observe any distinct change in CXCR5 expression in AC cases with increased tumor stage and nodal metastasis. Since the present study was limited to a small number of patients, subsequent studies with more patient samples from each group (SCC and AC) and subgroups (T1, ≥T2 and N0 and ≥N1) will provide conclusive information correlating CXCR5 expression in NSCLCs with disease progression and survival.

In our previous studies, we showed that serum CXCL13 levels correlated with prostatic disease and mediated PCa cell migration, integrin clustering, and cell adhesion (12). Here, for NSCLC patients, serum CXCL13 levels in ACs were higher
Singh et al.: cXcr5 in lung cancer

than in SCCs, which may be associated with the aggressiveness of the latter disease.

In view of the expression of CXCR5 in LuCa tissues and to understand the biological significance of CXCR5 expression, we stained and analyzed CXCR5 expression on two human LuCa cell lines, NSCLC (NCI-H1915) and SCLC (SW-1271). We also determined the migration potential of these cells under a chemotactic gradient of CXCL13. Staining and migration assay results were in accordance with the hypothesis that the CXCR5-CXCL13 axis is involved in LuCa cell dissemination and/or metastasis. SW-1271 cells, which had lower expression of CXCR5 relative to NCI-H1915 cells, were not as responsive to CXCL13 as were NCI-H1915 cells.

In conclusion, NSCLC tissues expressed CXCR5, which correlated with stage/grade of the disease. Higher CXCR5 expression and migration by NSCLC cells suggest a role in migration and metastasis of primary lung tumors in response to CXCL13. These findings indicate that differential expression patterns of CXCR5 and CXCL13 in two subtypes (SCC and AC) of NSCLC are associated with differences in their prognosis and survival. Identification of a sensitive tumor marker, predictive of diagnosis, prognosis, and drug sensitivity, would enhance NSCLC treatment and diagnosis. We propose that CXCR5/CXCL13, either alone or in combination, could be used as a prognostic biomarker for LuCa; however, this can be established only by larger studies in which these factors are evaluated in the same patients.
Acknowledgements

The content of this manuscript benefited from many fruitful conversations with members of the Morehouse School of Medicine, Atlanta, GA, USA; the University of Louisville, School of Medicine; and the University of Alabama at Birmingham. This study was supported by U54CA118638 and G12MD007602.

References

1. Esposito L, Conti D, Ailavajhala R, Khalil N and Giordano A: Lung cancer: are we up to the challenge? Curr Genomics 11: 513-518, 2010.
2. Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 83: 584-594, 2008.
3. Baird AM, Gray SG and O'Byrne KJ: Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One 6: e14593, 2011.
4. Lazennec G and Richmond A: Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16: 133-144, 2010.
5. Su L, Zhang J, Xu H, Wang Y, Chu Y, Liu R and Xiong S: Differential expression of CXCR4 is associated with the metastatic potential of human non-small cell lung cancer cells. Clin Cancer Res 11: 8273-8280, 2005.
6. Burger JA and Kipps TJ: CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 107: 1761-1767, 2006.
7. Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ and Burger JA: Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 110: 3316-3325, 2007.
8. Hussain SK, Zhu W, Chang SC, et al: Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-Hodgkin B-Cell lymphoma risk. Cancer Epidemiol Biomarkers Prev 22: 295-307, 2013.
9. Kurotova AV, Tamayo AT, Ford RJ and Burger JA: Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113: 4604-4613, 2009.
10. Chan CC, Shen D, Hackett JJ, Buggage RR and Tuaillon N: Expression of chemokine receptors, CXCR4 and CXCR5, and chemokines, BLC and SDF-1, in the eyes of patients with primary intraocular lymphoma. Ophthalmology 110: 421-426, 2003.
11. Singh S, Singh R, Singh UP, et al: Clinical and biological significance of CXCR5 expressed by prostate cancer specimens and cell lines. Int J Cancer 125: 2288-2295, 2009.
12. Singh S, Singh R, Sharma PK, et al: Serum CXCL13 positively correlates with prostatic disease, prostate-specific antigen and mediates prostate cancer cell invasion, integrin clustering and cell adhesion. Cancer Lett 283: 29-35, 2009.
13. Panse J, Friedrichs K, Marx A, et al: Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br J Cancer 99: 930-938, 2008.
14. Del Grosso F, Coco S, Scaruffi P, et al: Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors. Mol Cancer Res 9: 815-823, 2011.
15. Yuvaraj S, Griffin AC, Sundaram K, Kirkwood KL, Norris JS and Reddy SV: A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res 7: 1399-1407, 2009.
16. Airoldi I, Cocco C, Morandi F, Prigione I and Pistoa V: CXCR5 may be involved in the attraction of human metastatic neuroblastoma cells to the bone marrow. Cancer Immunol Immunother 57: 541-548, 2008.
17. El Haibi CP, Sharma PK, Singh R, Johnson PR, Sutcliffe J, Singh S and Lillard JW Jr: P13Kp10-, Src-, FAK-dependent and DOCK2-independent migration and invasion of CXCL13-stimulated prostate cancer cells. Mol Cancer 9: 85, 2010.
18. El-Haibi CP, Singh R, Sharma PK, Singh S and Lillard JW Jr: CXCL13 mediates prostate cancer cell proliferation through JNK signalling and invasion through ERK activation. Cell Prolif 44: 311-319, 2011.
19. Ikawaki S, Mino N, Takahashi T, et al: Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 115: 2580-2593, 2009.
20. Rollins BJ: Chemokines. Blood 90: 909-928, 1997.
21. Taub DD: Chemokine-leukocyte interactions. The voodoo that they do so well. Cytokine Growth Factor Rev 7: 355-376, 1996.
22. Sano JP, Andre F, Morat L, et al: Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol 15: 613-617, 2004.
23. Zha YM, Webster SJ, Flower D and Wolff PJ: Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer 91: 1970-1976, 2004.
24. Phillips RJ, Burdick MD, Lutz M, Belperio JA, Keane MP and Strieter RM: The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am J Respir Crit Care Med 167: 1676-1686, 2003.
25. Saintigny P, Massarelli E, Lin S, et al: CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma. Cancer Res 73: 571-582, 2013.
26. Chen JJ, Yao PL, Yuan A, et al: Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 9: 729-737, 2003.
27. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I and Katsuda Y: Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 110: 601-605, 1995.
28. Suzuki K, Nagai K, Yoshida J, Nishimura M, Takahashi K, Yokose T and Nishiwaki Y: Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 80: 1976-1984, 1999.